Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Altimmune (ALT) Short-Term Debt issuances (2012 - 2014)

Altimmune (ALT) reported Short-Term Debt issuances of -$1.1 million for Q1 2014, down 85593.88% year-over-year from N/an in Q1 2013, and down 200.0% on a QoQ basis from $1.1 million in Q4 2013.

Altimmune (ALT) has 3 years of Short-Term Debt issuances data on file, last reported at -$1.1 million in Q1 2014.

  • Quarterly Short-Term Debt issuances fell 85593.88% year-over-year to -$1.1 million in Q1 2014, while the trailing twelve-month figure through Dec 2014 was -$1.1 million (down 357.24% YoY) and the FY2014 annual result came in at -$1.1 million, down 357.24% from the prior year.
  • Short-Term Debt issuances eased to -$1.1 million in Q1 2014 per ALT's latest filing, from $1.1 million in the prior quarter.
  • Across five years, Short-Term Debt issuances topped out at $1.1 million in Q4 2013 and bottomed at -$1.2 million in Q3 2013.
  • The 3-year median for Short-Term Debt issuances is -$1274.0 (2013), against an average of -$50080.3.
  • The widest annual swing landed in 2013, when Short-Term Debt issuances jumped 793.87%; it then tumbled 85593.88% in 2014.
  • Tracing ALT's Short-Term Debt issuances over 3 years: stood at $122137.0 in 2012, then jumped by 793.87% to $1.1 million in 2013, then tumbled by 200.0% to -$1.1 million in 2014.
  • Per Business Quant, the three latest ALT Short-Term Debt issuances figures stand at -$1.1 million (Q1 2014), $1.1 million (Q4 2013), and -$1.2 million (Q3 2013).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Short-Term Debt issuances (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -33,000.00
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn -
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn -
10 Altimmune 379.61 Mn 379.61 Mn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2014 -1.09 Mn
Mar 31, 2014 -1.09 Mn
Dec 31, 2013 1.09 Mn
Dec 31, 2013 1.09 Mn
Sep 30, 2013 -1.17 Mn
Sep 30, 2013 -1.17 Mn
Jun 30, 2013 -161,090.00
Jun 30, 2013 -161,090.00
Mar 31, 2013 -1,274.00
Mar 31, 2013 -1,274.00
Dec 31, 2012 122,137.00
Dec 31, 2012 122,137.00
Mar 31, 2012 857,808.00
Mar 31, 2012 857,808.00